• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Safety profile of the combination treatment resulted good


    Safety profile of the combination treatment resulted good and toxicities easily manageable in both treatment groups. The weekly access to the clinic for T1 patients can reasonably explain the higher number of any grade adverse events observed in this Thonzonium Bromide treatment group, with an over-report of adverse events in the T1 arm. Despite this, the SENECA trial has confirmed old literature data according to which the weekly docetaxel schedule can be a preferable treatment option for patients suitable for second-line docetaxel, even with the association to nintedanib, owing to some advantages in toxicities and no shorter survival than the standard regimen. Three randomized phase III trials comparing weekly versus three-weekly docetaxel as second line chemotherapy for advanced NSCLC have been published in the past [[28], [29], [30]]: survival did not statistically differ between the two treatment arms of all these trials, while grade 3–4 haematologic toxicity was significantly more common in the q3wks arm. Data collected from patients during the study about quality of life (QoL) show that both T1 and T2 keep the perception of QoL stable and how the frequency of treatment does not modify the load for patients, being this not particularly burdensome. This data differs slightly from the literature that indicates that lung cancer is often associated with a greater symptom burden than other type of cancers [31,32]; this difference may be due to the fact that the LCSS evaluates in particular the physical and functional dimensions of the QoL and marginally those physical, social and spiritual ones that.
    Funding sources
    Acknowledgements We thank all the patients who participated in the study, their families, and all study center staff. All co-authors have contributed equally to this article, for what concern the conception of the work, the acquisition and interpretation of data, the writing and the final approval of the entire document. We thank Boehringer Ingelheim for the funding source provided for this study.
    Introduction Lung cancer is the leading cause of cancer-associated mortality worldwide, with non‑small cell lung cancer (NSCLC) accounting for the highest percentage. One of the new groups of molecular divisions of NSCLC: driver mutation, has shifted the treatment paradigm to targeted therapy [1]. Drugs designed specifically as inhibitors of molecularly selected targets have dramatically extended the survival times for patients whose tumors harbor actionable oncogenes such as EGFR mutation [2] or translocated ALK, RET, or ROS1 [[3], [4], [5]]. Given the intratumor heterogeneity of NSCLC at the molecular level [6,7], the biological behaviors of NSCLC may differ with respect to different oncogenes. An increasing number of studies have been made to investigate the biologic mechanism of gene mutated NSCLC, such as the associations between metastasis and gene alterations [8,9]. Comprehensive analysis of driver mutation genes and key cancer signaling pathways have become necessary to understand the genetic basis of diseases, biological behaviors, drug resistance, and to modify therapy options accordingly [10,11]. Increased adoption of low-dose spiral computed tomography has resulted in the increase of early-stage lung cancers being diagnosed [12]. Approximately 14.6–16.5% of patients with stage T1 NSCLC have subsequently been shown to have lymph node metastasis [13,14]. Patients with positive lymph node metastasis have a higher risk of disease recurrence [15]; thus, nodal status is one of the most predominant factors in the accurate staging of patients with resectable NSCLC. Precise status of nodal metastases is the key to deciding whether adjuvant therapy (chemotherapy or radiotherapy) should be delivered [16,17]. Furthermore, identification of associated predictors for lymph node metastasis, would enable the improvement in the strategy of the appropriate extent of lymphadenectomy in early stage NSCLC [18,19].